Complement-Independent Modulation of Influenza A Virus Infection by Factor H.
Animals
Anti-Inflammatory Agents
/ pharmacology
Complement Factor H
/ pharmacology
Complement Inactivating Agents
/ pharmacology
Complement System Proteins
/ physiology
Dogs
HEK293 Cells
Humans
Influenza A Virus, H1N1 Subtype
/ drug effects
Influenza A Virus, H3N2 Subtype
/ drug effects
Influenza, Human
/ immunology
Madin Darby Canine Kidney Cells
Virus Internalization
/ drug effects
complement
cytokine storm
factor H
influenza A virus
innate immunity
pseudotyped lentiviral particles
vaccinia virus complement control protein
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
01
2020
accepted:
13
02
2020
entrez:
10
4
2020
pubmed:
10
4
2020
medline:
2
3
2021
Statut:
epublish
Résumé
The complement system is an ancient innate immune defense mechanism that can recognize molecular patterns on the invading pathogens. Factor H, as an inhibitor of the alternative pathway, down-regulates complement activation on the host cell surface. Locally synthesized factor H at the site of infection/injury, including lungs, can act as a pattern recognition molecule without involving complement activation. Here, we report that factor H, a sialic acid binder, interacts with influenza A virus (IAV) and modulates IAV entry, as evident from down-regulation of matrix protein 1 (M1) in H1N1 subtype-infected cells and up-regulation of M1 expression in H3N2-infected A549 cells. Far-western blot revealed that factor H binds hemagglutinin (HA, ~70 kDa), neuraminidase (NA, ~60 kDa), and M1 (~25 kDa). IAV-induced transcriptional levels of IFN-α, TNF-α, IL-12, IL-6, IFN-α, and RANTES were reduced following factor H treatment for the H1N1 subtype at 6 h post-infection. However, for the H3N2 subtype, mRNA levels of these pro-inflammatory cytokines were enhanced. A recombinant form of vaccinia virus complement control protein (VCP), which like factor H, contains CCP modules and has complement-regulatory activity, mirrored the results obtained with factor H. Both factor H (25%), and VCP (45%) were found to reduce luciferase reporter activity in MDCK cells transduced with H1N1 pseudotyped lentiviral particles. Factor H (50%) and VCP (30%) enhanced the luciferase reporter activity for H3N2, suggesting an entry inhibitory role of factor H and VCP against H1N1, but not H3N2. Thus, factor H can modulate IAV infection and inflammatory responses, independent of its complement-related functions.
Identifiants
pubmed: 32269562
doi: 10.3389/fimmu.2020.00355
pmc: PMC7109256
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Complement Inactivating Agents
0
Complement Factor H
80295-65-4
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
355Informations de copyright
Copyright © 2020 Murugaiah, Varghese, Saleh, Tsolaki, Alrokayan, Khan, Collison, Sim, Nal, Al-Mohanna and Kishore.
Références
Front Immunol. 2018 Jul 30;9:1586
pubmed: 30105014
J Immunol. 1978 Oct;121(4):1437-45
pubmed: 701803
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16528-33
pubmed: 23012413
Methods Enzymol. 1993;223:13-35
pubmed: 8271948
Int J Med Microbiol. 2004 Apr;293 Suppl 37:152-7
pubmed: 15146998
PLoS Pathog. 2013;9(4):e1003308
pubmed: 23637600
Front Immunol. 2017 Jul 03;8:779
pubmed: 28717359
Hum Mol Genet. 2013 Dec 1;22(23):4857-69
pubmed: 23873044
Mol Immunol. 2008 Mar;45(5):1485-93
pubmed: 17915330
Crit Care. 2010;14(6):R203
pubmed: 21062445
J Virol. 2005 Mar;79(5):2814-22
pubmed: 15709000
J Clin Invest. 2011 Jan;121(1):6-13
pubmed: 21206092
Sci Rep. 2016 Nov 22;6:37045
pubmed: 27872472
Vaccine. 2008 Dec 30;26 Suppl 8:I113-7
pubmed: 19388175
Am J Pathol. 2010 Apr;176(4):1614-8
pubmed: 20167867
FEBS Lett. 2010 Feb 5;584(3):555-61
pubmed: 19945458
Cell Stem Cell. 2014 Aug 7;15(2):123-38
pubmed: 25105578
J Antimicrob Chemother. 2009 Feb;63(2):421-2
pubmed: 19022776
Am J Pathol. 2000 Jun;156(6):1951-9
pubmed: 10854218
Nat Rev Microbiol. 2014 Nov;12(11):739-49
pubmed: 25263223
Immunol Cell Biol. 2007 Feb-Mar;85(2):85-92
pubmed: 17213831
J Med Virol. 2001 Jul;64(3):262-8
pubmed: 11424113
Mol Immunol. 1993 May;30(7):679-84
pubmed: 8487783
Respir Physiol Neurobiol. 2011 Jan 31;175(1):185-7
pubmed: 21075220
Future Virol. 2011 Aug;6(8):951-962
pubmed: 21909336
Nat Med. 2002 Apr;8(4):373-8
pubmed: 11927943
J Biol Chem. 2000 Nov 24;275(47):37257-63
pubmed: 10967103
Mucosal Immunol. 2017 Nov;10(6):1581-1593
pubmed: 28327617
Cell Host Microbe. 2013 Jan 16;13(1):29-41
pubmed: 23332154
Exp Ther Med. 2016 Oct;12(4):2439-2446
pubmed: 27703505
J Virol Methods. 2017 Sep;247:107-113
pubmed: 28610903
J Virol. 2012 Jun;86(11):6055-66
pubmed: 22491448
J Biol Chem. 2012 Mar 23;287(13):9804-16
pubmed: 22318733
Nature. 2006 Mar 23;440(7083):435-6
pubmed: 16554799
J Virol. 2010 Aug;84(15):7613-24
pubmed: 20504916
Immunobiology. 2016 Sep;221(9):944-52
pubmed: 27262511
Vaccine. 2008 Dec 30;26 Suppl 8:I46-8
pubmed: 19388164
J Infect Dis. 1992 Dec;166(6):1245-50
pubmed: 1431243
Microbiol Mol Biol Rev. 2001 Mar;65(1):131-50
pubmed: 11238989
Viruses. 2013 Jun 10;5(6):1431-46
pubmed: 23752648
Virol J. 2013 Nov 22;10:321
pubmed: 24261589
Front Immunol. 2013 Apr 23;4:93
pubmed: 23630525
J Immunol. 2015 Nov 15;195(10):4986-98
pubmed: 26459349
Nat Rev Microbiol. 2008 Feb;6(2):132-42
pubmed: 18197169
Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32
pubmed: 22390970
Infect Drug Resist. 2017 Apr 20;10:121-134
pubmed: 28458567
Science. 1990 Nov 9;250(4982):827-30
pubmed: 2237434
Mol Immunol. 2017 Apr;84:84-106
pubmed: 28216098
J Virol. 2014 Aug;88(16):8981-97
pubmed: 24899188
Microbiol Rev. 1992 Mar;56(1):152-79
pubmed: 1579108
PLoS Pathog. 2013 Jan;9(1):e1003115
pubmed: 23326231
Nat Rev Microbiol. 2011 Jul 11;9(8):590-603
pubmed: 21747392
PLoS One. 2013 Jun 21;8(6):e66325
pubmed: 23805213
J Immunol. 2016 Feb 1;196(3):1239-48
pubmed: 26700768
Proc Natl Acad Sci U S A. 1990 May;87(10):3982-6
pubmed: 1692629
Rev Med Virol. 2016 Jul;26(4):242-50
pubmed: 27061123
J Biol Chem. 2001 Mar 16;276(11):8427-35
pubmed: 11113124
J Biol Chem. 2015 Nov 27;290(48):28977-87
pubmed: 26468283
N Engl J Med. 2005 Sep 29;353(13):1374-85
pubmed: 16192482
Immunobiology. 2001 Dec;204(5):603-13
pubmed: 11846225
Virol J. 2013 Apr 16;10:118
pubmed: 23587221
Nature. 2014 Jan 16;505(7483):412-6
pubmed: 24317696
J Immunol. 2010 Feb 15;184(4):1956-67
pubmed: 20089702
Trends Immunol. 2009 Dec;30(12):574-84
pubmed: 19864182
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
PLoS Pathog. 2008 Dec;4(12):e1000250
pubmed: 19112495
Scand J Immunol. 2004 Jan;59(1):1-15
pubmed: 14723616
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8924-9
pubmed: 15178763
Immunity. 2012 Aug 24;37(2):199-207
pubmed: 22921118
J Virol. 2008 Mar;82(6):2741-51
pubmed: 18199656